Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection
Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a HPV16 oncoprotein (E7), which was capable of preve...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2004-12, Vol.23 (5), p.629-638 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 638 |
|---|---|
| container_issue | 5 |
| container_start_page | 629 |
| container_title | Vaccine |
| container_volume | 23 |
| creator | Cheung, Ying-Kit Cheng, Samuel Chak-Sum Sin, Fion Wan-Yee Xie, Yong |
| description | Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a HPV16 oncoprotein (E7), which was capable of preventing HPV16 infection and eliminating HPV16-infected cells. A plasmid, L1E7hpSCA1, encoding the L1 and E7 genes with the codon usage optimized for mammalian cell expression, was constructed. Mutations were introduced into the E7 gene sequence for reducing its oncogenicity. C57BL/6 mice were intramuscularly immunized at tibialis anterior (TA) muscles with the newly constructed L1E7hpSCA1 plasmid. The immune responses induced by the L1E7hpSCA1 plasmid (with codon optimization) and a control L1E7pSCA1 plasmid (without codon optimization) were compared. It is shown that the L1E7hpSCA1 was able to induce much stronger immune responses than the L1E7pSCA1. Sera obtained from immunized animals were found to contain anti-HPV16 antibodies as detected by ELISA and hemagglutination inhibition (HAI) assays. Cytotoxicity and interferon-γ assays showed that spleenocytes from immunized animals were able to recognize and lyze E7 expressing tumor TC-1 cells. Moreover, the growth of E7 expressing tumor mass was inhibited in vaccinated mice. In vivo tumor protection test indicated that tumor formation was prevented in the experimental animals (67%) after vaccination with L1E7hpSCA1, while for the control group injected with L1E7pSCA1 only and the animal group injected with pSCA1 only, tumor formation was observed in all experimental animals. Our results suggest that the L1E7h gene (with codon optimization) is more effective against HPV16 than the L1E7 gene (without codon optimization). The L1E7hpSCA1 plasmid was able to provide protection against E7 expressing tumor, and it might have the potential to be a vaccine candidate for HPV prevention. |
| doi_str_mv | 10.1016/j.vaccine.2004.07.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17236877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X04005213</els_id><sourcerecordid>3420673681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-ce38febf15a6317cd2f123ae744c12a54b50b1f60bdd2ad4ca5db52a0b1c122a3</originalsourceid><addsrcrecordid>eNqFkV9rFDEUxYModq1-BCUgij7MmD-TzOyTlFatULQPVXwLmSSzvctMMk1mtqzfwG9tlh0o-OJTuDe_ezicg9BLSkpKqPywLXfaGPCuZIRUJalLQskjtKJNzQsmaPMYrQiTVVFR8usEPUtpSwgRnK6fohMqRMVow1foz3Wv0wAWO2-CBb_Box6h78OgdxDnhG_2o8NU4neX1z-pfI8vvp1hE3ya4mwmZ_E9TLd5YYPHYZxggN96gjzAMMawy8B06_IwzD5snAcD0x7rjYasgLMkBt85c7h4jp50uk_uxfKeoh-fP92cXxZX3798PT-7KkwlyFQYx5vOtR0VWnJaG8s6yrh2dVUZyrSoWkFa2knSWsu0rYwWthVM52X-Z5qfordH3ezvbnZpUgMk4_peexfmpGjNuGzqOoOv_wG3YY4-e1M5vzWRkq1JpsSRMjGkFF2nxgiDjntFiTo0pbZqaUodmlKkVrmpfPdqUZ_bwdmHq6WaDLxZAJ2M7ruovYH0wEnOpRBN5j4eOZdD24GLKhnIbToLMSerbID_WPkLz4O1xw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1559066290</pqid></control><display><type>article</type><title>Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Cheung, Ying-Kit ; Cheng, Samuel Chak-Sum ; Sin, Fion Wan-Yee ; Xie, Yong</creator><creatorcontrib>Cheung, Ying-Kit ; Cheng, Samuel Chak-Sum ; Sin, Fion Wan-Yee ; Xie, Yong</creatorcontrib><description>Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a HPV16 oncoprotein (E7), which was capable of preventing HPV16 infection and eliminating HPV16-infected cells. A plasmid, L1E7hpSCA1, encoding the L1 and E7 genes with the codon usage optimized for mammalian cell expression, was constructed. Mutations were introduced into the E7 gene sequence for reducing its oncogenicity. C57BL/6 mice were intramuscularly immunized at tibialis anterior (TA) muscles with the newly constructed L1E7hpSCA1 plasmid. The immune responses induced by the L1E7hpSCA1 plasmid (with codon optimization) and a control L1E7pSCA1 plasmid (without codon optimization) were compared. It is shown that the L1E7hpSCA1 was able to induce much stronger immune responses than the L1E7pSCA1. Sera obtained from immunized animals were found to contain anti-HPV16 antibodies as detected by ELISA and hemagglutination inhibition (HAI) assays. Cytotoxicity and interferon-γ assays showed that spleenocytes from immunized animals were able to recognize and lyze E7 expressing tumor TC-1 cells. Moreover, the growth of E7 expressing tumor mass was inhibited in vaccinated mice. In vivo tumor protection test indicated that tumor formation was prevented in the experimental animals (67%) after vaccination with L1E7hpSCA1, while for the control group injected with L1E7pSCA1 only and the animal group injected with pSCA1 only, tumor formation was observed in all experimental animals. Our results suggest that the L1E7h gene (with codon optimization) is more effective against HPV16 than the L1E7 gene (without codon optimization). The L1E7hpSCA1 plasmid was able to provide protection against E7 expressing tumor, and it might have the potential to be a vaccine candidate for HPV prevention.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2004.07.010</identifier><identifier>PMID: 15542183</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antibodies, Viral - blood ; Applied microbiology ; Biological and medical sciences ; Capsid Proteins ; Cervical cancer ; Codon ; Codon usage optimization ; Cytotoxicity ; Cytotoxicity Tests, Immunologic ; Deoxyribonucleic acid ; Disease Models, Animal ; DNA ; DNA vaccination ; Enzyme-Linked Immunosorbent Assay ; Female ; Fundamental and applied biological sciences. Psychology ; Genes ; Hemagglutination Inhibition Tests ; HPV16 infection ; Human papillomavirus ; Human papillomavirus 16 ; Immune system ; Immunization ; Immunogenicity ; Interferon-gamma - analysis ; Medical research ; Medical sciences ; Mice ; Mice, Inbred C57BL ; Microbiology ; Miscellaneous ; Muscles ; Mutation ; Oncogene Proteins, Viral - genetics ; Oncogene Proteins, Viral - immunology ; Papillomaviridae - genetics ; Papillomavirus E7 Proteins ; Papillomavirus Infections - prevention & control ; Papillomavirus Infections - virology ; Plasmids ; Tumors ; Uterine Cervical Neoplasms - prevention & control ; Uterine Cervical Neoplasms - virology ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, DNA - immunology ; Viral Vaccines - genetics ; Viral Vaccines - immunology ; Virology</subject><ispartof>Vaccine, 2004-12, Vol.23 (5), p.629-638</ispartof><rights>2004 Elsevier Ltd</rights><rights>2005 INIST-CNRS</rights><rights>Copyright Elsevier Limited Dec 16, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-ce38febf15a6317cd2f123ae744c12a54b50b1f60bdd2ad4ca5db52a0b1c122a3</citedby><cites>FETCH-LOGICAL-c450t-ce38febf15a6317cd2f123ae744c12a54b50b1f60bdd2ad4ca5db52a0b1c122a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1559066290?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16336558$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15542183$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheung, Ying-Kit</creatorcontrib><creatorcontrib>Cheng, Samuel Chak-Sum</creatorcontrib><creatorcontrib>Sin, Fion Wan-Yee</creatorcontrib><creatorcontrib>Xie, Yong</creatorcontrib><title>Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a HPV16 oncoprotein (E7), which was capable of preventing HPV16 infection and eliminating HPV16-infected cells. A plasmid, L1E7hpSCA1, encoding the L1 and E7 genes with the codon usage optimized for mammalian cell expression, was constructed. Mutations were introduced into the E7 gene sequence for reducing its oncogenicity. C57BL/6 mice were intramuscularly immunized at tibialis anterior (TA) muscles with the newly constructed L1E7hpSCA1 plasmid. The immune responses induced by the L1E7hpSCA1 plasmid (with codon optimization) and a control L1E7pSCA1 plasmid (without codon optimization) were compared. It is shown that the L1E7hpSCA1 was able to induce much stronger immune responses than the L1E7pSCA1. Sera obtained from immunized animals were found to contain anti-HPV16 antibodies as detected by ELISA and hemagglutination inhibition (HAI) assays. Cytotoxicity and interferon-γ assays showed that spleenocytes from immunized animals were able to recognize and lyze E7 expressing tumor TC-1 cells. Moreover, the growth of E7 expressing tumor mass was inhibited in vaccinated mice. In vivo tumor protection test indicated that tumor formation was prevented in the experimental animals (67%) after vaccination with L1E7hpSCA1, while for the control group injected with L1E7pSCA1 only and the animal group injected with pSCA1 only, tumor formation was observed in all experimental animals. Our results suggest that the L1E7h gene (with codon optimization) is more effective against HPV16 than the L1E7 gene (without codon optimization). The L1E7hpSCA1 plasmid was able to provide protection against E7 expressing tumor, and it might have the potential to be a vaccine candidate for HPV prevention.</description><subject>Animals</subject><subject>Antibodies, Viral - blood</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Capsid Proteins</subject><subject>Cervical cancer</subject><subject>Codon</subject><subject>Codon usage optimization</subject><subject>Cytotoxicity</subject><subject>Cytotoxicity Tests, Immunologic</subject><subject>Deoxyribonucleic acid</subject><subject>Disease Models, Animal</subject><subject>DNA</subject><subject>DNA vaccination</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genes</subject><subject>Hemagglutination Inhibition Tests</subject><subject>HPV16 infection</subject><subject>Human papillomavirus</subject><subject>Human papillomavirus 16</subject><subject>Immune system</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Interferon-gamma - analysis</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Microbiology</subject><subject>Miscellaneous</subject><subject>Muscles</subject><subject>Mutation</subject><subject>Oncogene Proteins, Viral - genetics</subject><subject>Oncogene Proteins, Viral - immunology</subject><subject>Papillomaviridae - genetics</subject><subject>Papillomavirus E7 Proteins</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>Papillomavirus Infections - virology</subject><subject>Plasmids</subject><subject>Tumors</subject><subject>Uterine Cervical Neoplasms - prevention & control</subject><subject>Uterine Cervical Neoplasms - virology</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, DNA - immunology</subject><subject>Viral Vaccines - genetics</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkV9rFDEUxYModq1-BCUgij7MmD-TzOyTlFatULQPVXwLmSSzvctMMk1mtqzfwG9tlh0o-OJTuDe_ezicg9BLSkpKqPywLXfaGPCuZIRUJalLQskjtKJNzQsmaPMYrQiTVVFR8usEPUtpSwgRnK6fohMqRMVow1foz3Wv0wAWO2-CBb_Box6h78OgdxDnhG_2o8NU4neX1z-pfI8vvp1hE3ya4mwmZ_E9TLd5YYPHYZxggN96gjzAMMawy8B06_IwzD5snAcD0x7rjYasgLMkBt85c7h4jp50uk_uxfKeoh-fP92cXxZX3798PT-7KkwlyFQYx5vOtR0VWnJaG8s6yrh2dVUZyrSoWkFa2knSWsu0rYwWthVM52X-Z5qfordH3ezvbnZpUgMk4_peexfmpGjNuGzqOoOv_wG3YY4-e1M5vzWRkq1JpsSRMjGkFF2nxgiDjntFiTo0pbZqaUodmlKkVrmpfPdqUZ_bwdmHq6WaDLxZAJ2M7ruovYH0wEnOpRBN5j4eOZdD24GLKhnIbToLMSerbID_WPkLz4O1xw</recordid><startdate>20041216</startdate><enddate>20041216</enddate><creator>Cheung, Ying-Kit</creator><creator>Cheng, Samuel Chak-Sum</creator><creator>Sin, Fion Wan-Yee</creator><creator>Xie, Yong</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20041216</creationdate><title>Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection</title><author>Cheung, Ying-Kit ; Cheng, Samuel Chak-Sum ; Sin, Fion Wan-Yee ; Xie, Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-ce38febf15a6317cd2f123ae744c12a54b50b1f60bdd2ad4ca5db52a0b1c122a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Animals</topic><topic>Antibodies, Viral - blood</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Capsid Proteins</topic><topic>Cervical cancer</topic><topic>Codon</topic><topic>Codon usage optimization</topic><topic>Cytotoxicity</topic><topic>Cytotoxicity Tests, Immunologic</topic><topic>Deoxyribonucleic acid</topic><topic>Disease Models, Animal</topic><topic>DNA</topic><topic>DNA vaccination</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genes</topic><topic>Hemagglutination Inhibition Tests</topic><topic>HPV16 infection</topic><topic>Human papillomavirus</topic><topic>Human papillomavirus 16</topic><topic>Immune system</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Interferon-gamma - analysis</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Microbiology</topic><topic>Miscellaneous</topic><topic>Muscles</topic><topic>Mutation</topic><topic>Oncogene Proteins, Viral - genetics</topic><topic>Oncogene Proteins, Viral - immunology</topic><topic>Papillomaviridae - genetics</topic><topic>Papillomavirus E7 Proteins</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>Papillomavirus Infections - virology</topic><topic>Plasmids</topic><topic>Tumors</topic><topic>Uterine Cervical Neoplasms - prevention & control</topic><topic>Uterine Cervical Neoplasms - virology</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, DNA - immunology</topic><topic>Viral Vaccines - genetics</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheung, Ying-Kit</creatorcontrib><creatorcontrib>Cheng, Samuel Chak-Sum</creatorcontrib><creatorcontrib>Sin, Fion Wan-Yee</creatorcontrib><creatorcontrib>Xie, Yong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheung, Ying-Kit</au><au>Cheng, Samuel Chak-Sum</au><au>Sin, Fion Wan-Yee</au><au>Xie, Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2004-12-16</date><risdate>2004</risdate><volume>23</volume><issue>5</issue><spage>629</spage><epage>638</epage><pages>629-638</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Human papillomavirus Type 16 (HPV16) infections can cause neoplasia, which is thought to be closely associated with the development of cervical cancers. In the study, we attempted to construct a DNA plasmid encoding a HPV16 capsid protein (L1) and a HPV16 oncoprotein (E7), which was capable of preventing HPV16 infection and eliminating HPV16-infected cells. A plasmid, L1E7hpSCA1, encoding the L1 and E7 genes with the codon usage optimized for mammalian cell expression, was constructed. Mutations were introduced into the E7 gene sequence for reducing its oncogenicity. C57BL/6 mice were intramuscularly immunized at tibialis anterior (TA) muscles with the newly constructed L1E7hpSCA1 plasmid. The immune responses induced by the L1E7hpSCA1 plasmid (with codon optimization) and a control L1E7pSCA1 plasmid (without codon optimization) were compared. It is shown that the L1E7hpSCA1 was able to induce much stronger immune responses than the L1E7pSCA1. Sera obtained from immunized animals were found to contain anti-HPV16 antibodies as detected by ELISA and hemagglutination inhibition (HAI) assays. Cytotoxicity and interferon-γ assays showed that spleenocytes from immunized animals were able to recognize and lyze E7 expressing tumor TC-1 cells. Moreover, the growth of E7 expressing tumor mass was inhibited in vaccinated mice. In vivo tumor protection test indicated that tumor formation was prevented in the experimental animals (67%) after vaccination with L1E7hpSCA1, while for the control group injected with L1E7pSCA1 only and the animal group injected with pSCA1 only, tumor formation was observed in all experimental animals. Our results suggest that the L1E7h gene (with codon optimization) is more effective against HPV16 than the L1E7 gene (without codon optimization). The L1E7hpSCA1 plasmid was able to provide protection against E7 expressing tumor, and it might have the potential to be a vaccine candidate for HPV prevention.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>15542183</pmid><doi>10.1016/j.vaccine.2004.07.010</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2004-12, Vol.23 (5), p.629-638 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_17236877 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Animals Antibodies, Viral - blood Applied microbiology Biological and medical sciences Capsid Proteins Cervical cancer Codon Codon usage optimization Cytotoxicity Cytotoxicity Tests, Immunologic Deoxyribonucleic acid Disease Models, Animal DNA DNA vaccination Enzyme-Linked Immunosorbent Assay Female Fundamental and applied biological sciences. Psychology Genes Hemagglutination Inhibition Tests HPV16 infection Human papillomavirus Human papillomavirus 16 Immune system Immunization Immunogenicity Interferon-gamma - analysis Medical research Medical sciences Mice Mice, Inbred C57BL Microbiology Miscellaneous Muscles Mutation Oncogene Proteins, Viral - genetics Oncogene Proteins, Viral - immunology Papillomaviridae - genetics Papillomavirus E7 Proteins Papillomavirus Infections - prevention & control Papillomavirus Infections - virology Plasmids Tumors Uterine Cervical Neoplasms - prevention & control Uterine Cervical Neoplasms - virology Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Vaccines, DNA - immunology Viral Vaccines - genetics Viral Vaccines - immunology Virology |
| title | Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A47%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasmid%20encoding%20papillomavirus%20Type%2016%20(HPV16)%20DNA%20constructed%20with%20codon%20optimization%20improved%20the%20immunogenicity%20against%20HPV%20infection&rft.jtitle=Vaccine&rft.au=Cheung,%20Ying-Kit&rft.date=2004-12-16&rft.volume=23&rft.issue=5&rft.spage=629&rft.epage=638&rft.pages=629-638&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2004.07.010&rft_dat=%3Cproquest_cross%3E3420673681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1559066290&rft_id=info:pmid/15542183&rft_els_id=S0264410X04005213&rfr_iscdi=true |